<i id='FFC5EA4BCA'><strike id='FFC5EA4BCA'><tt id='FFC5EA4BCA'><pre id='FFC5EA4BCA'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Jerome Adams on the need for new antivirals for Covid 
How to keep neuroscience’s past racism from being its future 
Medical records are filled with copy 
Alcohol isn't healthy after all. Will new dietary guidelines reflect that? 
Continuity nursing helped my family in our darkest PICU moments 
Apple Watch's A 
Duchenne breakthrough therapy leaves behind pioneering families 
Why health records don't always know when patients are dead 
Medicare proposal to cover medical devices draws a mixed reaction 
Grail spinoff by Illumina should end disastrous merger attempt
Medical records are filled with copy 
Bird flu outbreak in cows is latest avian flu curveball 
In Memoriam: Notable people who died in 2023 
Researchers on aging grapple with how to calculate biological age 
In age of alternative facts, a scholarly course on calling out crap 
